invasive aspergillosis
Infectious disease · 2006–2006
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| posaconazole Treatment of invasive fungal infections (invasive aspergillosis, fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma) in patients 13… | Jul 2006 | Recommended with restriction | no section in document |
What the PBS pays
$9M in government benefit over 2024–25, across 18,217 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| posaconazole | $9M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| caspofunginCANCIGIN caspofungin (as acetate) 50mg powder for injection vial | 2016 | 22 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.